Approval · Notice of Compliance 29290 · 2022
IMITREX: Notice of Compliance 29290
Issued October 24, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 29290
- Date
- October 24, 2022
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To update labels and Product Monograph with a new standard claim for IMITREX and IMITREX (Nasal Spray)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| IMITREX | Not yet assigned | — |
| IMITREX DF | Not yet assigned | — |
| IMITREX NASAL SPRAY | Not yet assigned | — |
Medicinal ingredients
- SUMATRIPTAN SUCCINATE 6 MG per 0.5ML
- SUMATRIPTAN SUCCINATE 50 MG per TAB
- SUMATRIPTAN SUCCINATE 100 MG per TAB
- SUMATRIPTAN HEMISULFATE 5 MG per ACT
- SUMATRIPTAN HEMISULFATE 20 MG per ACT